α-Conotoxins are disulfide-rich peptides that target nicotinic acetylcholine receptors. Recently we identified several α-conotoxins that also modulate voltage-gated calcium channels by acting as G protein-coupled GABA(B) receptor (GABA(B)R) agonists. These α-conotoxins are promising drug leads for the treatment of chronic pain. To elucidate the diversity of α-conotoxins that act through this mechanism, we synthesized and characterized a set of peptides with homology to α-conotoxins known to inhibit high voltage-activated calcium channels via GABA(B)R activation. Remarkably, all disulfide isomers of the active α-conotoxins Pu1.2 and Pn1.2, and the previously studied Vc1.1 showed similar levels of biological activity. Structure determination by NMR spectroscopy helped us identify a simplified biologically active eight residue peptide motif containing a single disulfide bond that is an excellent lead molecule for developing a new generation of analgesic peptide drugs.
Covalently attached peptide dendrimers can enhance binding affinity and functional activity. Homogenous di- and tetravalent dendrimers incorporating the α7-nicotinic receptor blocker α-conotoxin ImI (α-ImI) with polyethylene glycol spacers were designed and synthesized via a copper-catalyzed azide-alkyne cycloaddition of azide-modified α-ImI to an alkyne-modified polylysine dendron. NMR and CD structural analysis confirmed that each α-ImI moiety in the dendrimers had the same 3D structure as native α-ImI. The binding of the α-ImI dendrimers to binding protein Ac-AChBP was measured by surface plasmon resonance and revealed enhanced affinity. Quantitative electrophysiology showed that α-ImI dendrimers had ∼100-fold enhanced potency at hα7 nAChRs (IC50 = 4 nM) compared to native α-ImI (IC50 = 440 nM). In contrast, no significant potency enhancement was observed at heteromeric hα3β2 and hα9α10 nAChRs. These findings indicate that multimeric ligands can significantly enhance conotoxin potency and selectivity at homomeric nicotinic ion channels.
α9α10 nicotinic acetylcholine receptors (nAChRs) putatively exist at different stoichiometries. We systematically investigated the molecular determinants of α-conotoxins Vc1.1, RgIA#, and PeIA inhibition at hypothetical stoichiometries of the human α9α10 nAChR. Our results suggest that only Vc1.1 exhibits stoichiometric-dependent inhibition at the α9α10 nAChR. The hydrogen bond between N154 of α9 and D11 of Vc1.1 at the α9(+)-α9(-) interface is responsible for the stoichiometric-dependent potency of Vc1.1.
The
affinity of α-conotoxins, a class of nicotinic acetylcholine
receptor (nAChR) peptide inhibitors, can be enhanced by dendrimerization.
It has been hypothesized that this improvement arose from simultaneous
binding of the α-conotoxins to several spatially adjacent sites.
We here engineered several α-conotoxin dimers using a linker
length compatible between neighboring binding sites on the same receptor.
Remarkably, the dimer of α-conotoxin PeIA compared to the monomer
displayed an increase in potency by 11-fold (IC50 = 1.9
nM) for the human α9α10 nAChR. The dimerization of α-conotoxin
RgIA# resulted in a dual inhibitor that targets both α9α10
and α7 nAChR subtypes with an IC50 = ∼50 nM.
The RgIA# dimer is therapeutically interesting because it is the first
dual inhibitor that potently and selectively inhibits these two nAChR
subtypes, which are both involved in the etiology of several cancers.
We propose that the dimerization of α-conotoxins is a simpler
and efficient alternative strategy to dendrimers for enhancing the
activity of α-conotoxins.
α-Conotoxins are disulfide-bonded peptides from cone snail venoms and are characterized by their affinity for nicotinic acetylcholine receptors (nAChR). Several α-conotoxins with distinct selectivity for nAChR subtypes have been identified as potent analgesics in animal models of chronic pain. However, a number of α-conotoxins have been shown to inhibit N-type calcium channel currents in rodent dissociated dorsal root ganglion (DRG) neurons via activation of G protein-coupled GABA receptors (GABAR). Therefore, it is unclear whether activation of GABAR or inhibition of α9α10 nAChRs is the analgesic mechanism. To investigate the mechanisms by which α-conotoxins provide analgesia, we synthesized a suite of Vc1.1 analogues where all residues, except the conserved cysteines, in Vc1.1 were individually replaced by alanine (A), lysine (K), and aspartic acid (D). Our results show that the amino acids in the first loop play an important role in binding of the peptide to the receptor, whereas those in the second loop play an important role for the selectivity of the peptide for the GABAR over α9α10 nAChRs. We designed a cVc1.1 analogue that is >8000-fold selective for GABAR-mediated inhibition of high voltage-activated (HVA) calcium channels over α9α10 nAChRs and show that it is analgesic in a mouse model of chronic visceral hypersensitivity (CVH). cVc1.1[D11A,E14A] caused dose-dependent inhibition of colonic nociceptors with greater efficacy in ex vivo CVH colonic nociceptors relative to healthy colonic nociceptors. These findings suggest that selectively targeting GABAR-mediated HVA calcium channel inhibition by α-conotoxins could be effective for the treatment of chronic visceral pain.
Edited by Paul Fraser␣-Conotoxins represent a large group of pharmacologically active peptides that antagonize nicotinic acetylcholine receptors (nAChRs). The ␣34 nAChR, a predominant subtype in the peripheral nervous system, has been implicated in various pathophysiological conditions. As many ␣-conotoxins have multiple pharmacological targets, compounds specifically targeting individual nAChR subtypes are needed. In this study, we performed mutational analyses to evaluate the key structural components of human 2 and 4 nAChR subunits that determine ␣-conotoxin selectivity for ␣34 nAChR. ␣-Conotoxin RegIIA was used to evaluate the impact of non-conserved human 2 and 4 residues on peptide affinity. Two mutations, ␣32[T59K] and ␣32[S113R], strongly enhanced RegIIA affinity compared with wild-type ␣32, as seen by substantially increased inhibitory potency and slower off-rate kinetics. Opposite point mutations in ␣34 had the contrary effect, emphasizing the importance of loop D residue 59 and loop E residue 113 as determinants for RegIIA affinity. Molecular dynamics simulation revealed the side chains of 4 Lys 59 and 4 Arg 113 formed hydrogen bonds with RegIIA loop 2 atoms, whereas the 2 Thr 59 and 2 Ser 113 side chains were not long enough to form such interactions. Residue 4 Arg 113 has been identified for the first time as a crucial component facilitating antagonist binding. Another ␣-conotoxin, AuIB, exhibited low activity at human ␣32 and ␣34 nAChRs. Molecular dynamics simulation indicated the key interactions with the  subunit are different to RegIIA. Taken together, these data elucidate the interactions with specific individual  subunit residues that critically determine affinity and pharmacological activity of ␣-conotoxins RegIIA and AuIB at human nAChRs.
The main objective of this study was to determine whether (E)-3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2) and its structural derivative DM489 produce anti-neuropathic pain activity using the streptozotocin (STZ)-and oxaliplatin-induced neuropathic pain animal models. To assess possible mechanisms of action, the pharmacological activity of these compounds was determined at α7 and α9α10 nicotinic acetylcholine receptors (nAChRs) and Ca V 2.2 channels expressed alone or coexpressed with G protein-coupled GABA B receptors. The animal results indicated that a single dose of 3 mg/kg PAM-2 or DM489 decreases STZ-induced neuropathic pain in mice, and chemotherapy-induced neuropathic pain is decreased by PAM-2 (3 mg/ kg) and DM489 (10 mg/kg). The observed anti-neuropathic pain activity was inhibited by the α7-selective antagonist methyllycaconitine. The coadministration of oxaliplatin with an inactive dose (1 mg/kg) of PAM-2 decreased the development of neuropathic pain after 14, but not 7, days of cotreatment. The electrophysiological results indicated that PAM-2 potentiates human (h) and rat (r) α7 nAChRs with 2−7 times higher potency than that for hCa V 2.2 channel inhibition and an even greater difference compared to that for rα9α10 nAChR inhibition. These results support the notion that α7 nAChR potentiation is likely the predominant molecular mechanism underlying the observed anti-nociceptive pain activity of these compounds.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.